“…Proof-of-concept RMD-based NIPD studies have been carried out using dPCR technologies for several monogenic conditions [69,70] , including β-thalassaemia [71,72] , sickle cell disease [73,74] , monogenic diabetes [75] , haemophilia [76,77] , cystic fibrosis [59,78] , methylmalonic acidaemia [79] , inherited deafness [80,81] , as well as a small bespoke cohort with a number of different inheritance patterns [73] . A ddPCR-based RMD method has also been employed for NIPD of families at risk of spinal muscular atrophy, involving molecular counting of the copies of the SMN1 gene in cfDNA of mothers who carry only one functional copy [82] .…”